The Global Anti-Infectives Market Outlook to 2011

Table of Contents

Executive Summary

• Patient potential
• Global market analysis
• Pipeline analysis
• Competitive landscape

Chapter 1 Epidemiology of Anti-infectives market

• Summary
• Introduction
• Bacterial infections
• Overview
  • Respiratory tract infections
  • Urinary tract infections
  • Skin and skin structure infections
• Diagnosis, treatment and management
  • Respiratory tract infections
  • Urinary tract infections
  • Skin and skin structure infections
• Epidemiology
  • Respiratory tract infections
  • Urinary tract infections
  • Skin and skin structure infections
• Forecast epidemiology
  • Respiratory tract infections
  • Urinary tract infections
  • Skin and skin structure infections
• Viral infections
• Hepatitis
  • Overview
  • Diagnosis, treatment and management
  • Epidemiology
  • Forecast epidemiology
• Influenza
  • Overview
  • Diagnosis, treatment and management
  • Epidemiology
  • Forecast epidemiology
• Herpes
  • Overview
  • Diagnosis, treatment and management
  • Epidemiology
  • Forecast epidemiology
• Vaccines
• Tetanus, diphtheria, pertussis
  • Overview
  • Diagnosis, treatment and management
  • Epidemiology
• Mumps, measles and rubella
  • Overview
  • Diagnosis, treatment and management
  • Epidemiology
• Polio
  • Overview
  • Diagnosis, treatment and management
  • Epidemiology
• Fungal infections
• Overview
• Diagnosis, treatment and management
• Epidemiology
• Forecast epidemiology

Chapter 2 Global market analysis

• Summary
• Introduction
• Market analysis by country
• Licensing trends
• Market analysis by drug class
• Leading brands dynamics
• Key events in the anti-infectives market
• Safety warning issued for Sanofi-Aventis' Ketek (telithromycin)
• Serious adverse effects reported with the use of penicillins
• Launch of new innovative class of drugs
• Wyeth' s Prevnar gains from being the first vaccine to reach blockbuster status in 2005
• Increased competition within the hepatitis B market
• Arrival of generic competition to market leading products in the antiinfectives' market
• Anti-virals
• Leading brands of anti-viral treatments
  • Key brands analysis
• Anti-Virals sales forecasts to 2011
• Vaccines
  • Key brands analysis
• Vaccines sales forecasts to 2011
• Anti-bacterials
• Market analysis by drug class
• Leading brands of anti-bacterial treatments
• Macrolides
  • Key brands analysis
• Beta-lactams
  • Key brands analysis
• Other anti-biotics
  • Key brand analysis
• Penicillins
  • Market dynamics
  • Key brands analysis
• Cephalosporins market analysis
  • Market dynamics
  • Key brands analysis
• Tetracyclines market analysis
  • Market dynamics
  • Key brands analysis
• Fluroquinolones
  • Market dynamics
  • Key brands analysis
• Anti-bacterials sales forecasts to 2011
• Anti-fungals
• Market analysis by drug class
• Leading brands of the anti-fungal market
  • Market dynamics
  • Key brands analysis
• Anti-fungals sales forecasts to 2011
• Total anti-infective market sales forecasts to 2011

Chapter 3 Pipeline analysis

• Summary
• Introduction
• Key trends in R&D
• The therapeutic area pipeline
• Leading drugs in development
• Profiles of key pipeline products
• Phase III compounds
  • Albuferon (albinterferon alpha 2b)
  • Maribavir
  • Ceftobiprole
• Drugs in registration
  • Arbelic (telavancin)
  • Zeven (dalbavancin)
  • Mycograb (efungumab)
• Recently marketed drugs
  • Tygacil (tigecycline)
  • Doripenem
  • Baraclude (entecavir)
  • Tyzeka/Sebivo (telbivudine)
  • Noxafil (posaconazole)
  • Eraxis (anidulafungin)
• Pipeline forecasts
• Factors affecting forecasts
• Anti-infectives pipeline forecasts

Chapter 4 Competitive landscape

• Summary
• Introduction
• Company market shares
• GlaxoSmithKline
• Overview
• Sales focus by drug class
• Marketed product portfolio
• R&D pipeline analysis
• Strategic and growth analysis
  • Drivers of growth
  • Resistors of growth
• Pfizer
• Overview
• Sales focus by drug class
• Marketed product portfolio
• R&D pipeline analysis
• Strategic and growth analysis
  • Drivers of growth
  • Resistors of growth
• Novartis
• Overview
• Sales focus by drug class
• Marketed product portfolio
• R&D pipeline analysis
• Strategic and growth analysis
  • Drivers of growth
  • Resistors of growth
• Sanofi-Aventis
• Overview
• Sales focus by drug class
• Marketed product portfolio
• R&D pipeline analysis
• Strategic and growth analysis
  • Drivers of growth
  • Resistors of growth
• Merck
• Overview
• Sales focus by drug class
• Marketed product portfolio
• R&D pipeline analysis
• Strategic and growth analysis
  • Drivers of growth
  • Resistors of growth
• Johnson & Johnson
• Overview
• Sales focus by drug class
• Marketed product portfolio
• R&D pipeline analysis
• Strategic and growth analysis
  • Drivers of growth
  • Resistors of growth
• Roche
• Overview
• Sales focus by drug class
• Marketed product portfolio
• R&D pipeline analysis
• Strategic and growth analysis
  • Drivers of growth
  • Resistors of growth
• Wyeth
• Overview
• Sales focus by drug class
• Marketed product portfolio
• R&D pipeline analysis
• Strategic and growth analysis
  • Drivers of growth
  • Resistors of growth
• Abbott
• Overview
• Sales focus by drug class
• Marketed product portfolio
• R&D pipeline analysis
• Strategic and growth analysis
  • Drivers of growth
  • Resistors of growth
• Schering-Plough
• Overview
• Sales focus by drug class
• Marketed product portfolio
• R&D pipeline analysis
• Strategic and growth analysis
  • Drivers of growth
  • Resistors of growth

Chapter 5 Appendix

• IMS data
• J1 Systemic antibiotics
• J2 systemic agents for fungal infections
• J3 systemic sulphonamides
• J5 Antivirals for systemic use
• J7 Vaccines
• Index

List of Figures

• Figure 2.1: Global anti-infectives market share by geography, 2005
• Figure 2.2: Sales of types of anti-infectives brands, 2004-5
• Figure 2.3: Competitive dynamics of the drug classes in the global anti-infectives market, 2004-
• Figure 2.4: Competitive dynamics of the drug classes in the global anti-infectives market, 2004-
• Figure 2.5: Competitive dynamics of the leading anti-viral treatments in the global anti-infectives market, 2004-5
• Figure 2.6: Competitive dynamics of the leading vaccines in the global anti-infectives market, 2004-5
• Figure 2.7: Competitive dynamics of the global anti-bacterial market by drug class, 2005
• Figure 2.8: Competitive dynamics of the ten leading brands in the anti-bacterial drug class, 2005
• Figure 2.9: Competitive dynamics of the ten leading brands in the anti-fungal drug class, 2005
• Figure 3.10: Prevailing R&D approaches, 2006
• Figure 3.11: The anti-infectives pipeline by indication and stage of development, 2006
• Figure 3.12: Leading recently launched products and late-stage R&D in the anti-infectives market, 2005
• Figure 4.13: Competitive dynamics of the leading players in the global anti-infectives market, 2005
• Figure 4.14: GSK' s anti-infectives sales, 2005
• Figure 4.15: Pfizer' s anti-infectives sales, 2005
• Figure 4.16: Novartis' anti-infectives sales, 2005
• Figure 4.17: Sanofi-Aventis' anti-infectives sales, 2005
• Figure 4.18: Merck' s anti-infectives sales, 2005
• Figure 4.19: Johnson & Johnson anti-infectives sales, 2005
• Figure 4.20: Roche' s anti-infectives sales, 2005
• Figure 4.21: Wyeth' s anti-infectives sales, 2005
• Figure 4.22: Abbott' s anti-infectives sales, 2005
• Figure 4.23: Schering-Plough' s anti-infectives sales, 2005

List of Tables

• Table 1.1: Estimated prevalence of infective diseases across seven major pharmaceutical markets, 2005
• Table 1.2: Estimated incidence of community acquired pneumonia infections across seven major markets, 2005
• Table 1.3: Estimated incidence of uRTIs caused by streptococcus infection across seven major markets, 2005
• Table 1.4: Estimated incidence of community acquired urinary tract infections across seven major markets, 2005
• Table 1.5: Estimated incidence of bacterial skin and skin structure infections across seven major markets, 2005
• Table 1.6: Forecast epidemiology of CAP across the seven major markets, 2005-11
• Table 1.7: Forecast epidemiology of uRTIs caused by streptococcus infection across the seven major markets, 2005-11
• Table 1.8: Forecast epidemiology of urinary tract infections across the seven major markets, 2005-11
• Table 1.9: Forecast epidemiology of skin and skin structure infections across the seven major markets, 2005-11
• Table 1.10: Estimated prevalence of HBV and HCV across the seven major markets, 2005
• Table 1.11: Forecast epidemiology of HBV and HCV across the seven major markets, 2005-11
• Table 1.12: Estimated prevalence of influenza across the seven major markets, 2005
• Table 1.13: Estimated seroprevalence of HSV-1 and HSV-2 across the seven major markets, 2005
• Table 1.14: Forecast seroprevalence of HSV-1 and HSV-2 across the seven major markets, 2005-11
• Table 1.15: Estimated vaccine coverage and incidence of DPT across the seven major markets, 2005
• Table 1.16: Estimated vaccine coverage and incidence of MMR across the seven major markets, 2005
• Table 1.17: Estimated vaccine coverage and incidence of polio across the seven major markets, 2005
• Table 1.18: Estimated incidence of systemic fungal infections in across seven major markets, 2005
• Table 1.19: Forecast epidemiology of systemic fungal infections across the seven major markets, 2005-11
• Table 2.20: Breakdown of the global Anti-infective market by drug class, 2001-05
• Table 2.21: Leading brands in the global Anti-infectives market, 2004-05
• Table 2.22: Breakdown of the global anti-viral market by drug class, 2001-05
• Table 2.23: Leading anti-virals in the global anti-infectives market,
• Table 2.24: Anti-virals sales forecast, 2005-11
• Table 2.25: Leading vaccines in the global anti-infectives market,
• Table 2.26: Vaccines sales forecast, 2005-11
• Table 2.27: Breakdown of the global anti-bacterial market by drug class, 2001-05
• Table 2.28: Leading Anti-bacterials in the global anti-infectives market,
• Table 2.29: Leading macrolides in the global anti-infectives market,
• Table 2.30: Overview of Pfizer' s Zithromax franchise
• Table 2.31: Leading ' other' beta-lactams in the global anti-infectives market,
• Table 2.32: Leading ' other' anti-biotics in the global anti-infectives market,
• Table 2.33: Leading penicillins in the global anti-infectives market,
• Table 2.34: Leading cephalosporin brands in the global anti-bacterials market, 2004-05
• Table 2.35: Leading tetracycline brands in the global anti-bacterials market, 2004-05
• Table 2.36: Leading fluoroquinolones brands in the global anti-infectives market, 2004-5
• Table 2.37: Anti-bacterials' sales forecast, 2005-11
• Table 2.38: Anti-bacterials' sales forecast, 2005-11
• Table 2.39: Anti-bacterials' sales forecast, 2005-11
• Table 2.40: The global anti-fungal market by drug class, 2001-05
• Table 2.41: Leading anti-fungals brands in the global anti-infectives market, 2004-5
• Table 2.42: Anti-fungal sales forecast, 2005-11
• Table 2.43: Therapeutic sales forecasts by drug class, 2005-11
• Table 3.44: Anti-infectives pipeline forecasts, 2006-11
• Table 4.45: Leading players in the global anti-infectives market, 2004-5
• Table 4.46: GSK' s anti-infectives product portfolio, 2004-5
• Table 4.47: GSK' s anti-infectives R&D product pipeline, 2006
• Table 4.48: Pfizer' s anti-infectives product portfolio, 2004-5
• Table 4.49: Pfizer' s anti-infectives R&D product pipeline, 2006
• Table 4.50: Novartis' anti-infectives product portfolio, 2004-5
• Table 4.51: Novartis' anti-infectives R&D product pipeline, 2006
• Table 4.52: Sanofi-Aventis' anti-infectives product portfolio, 2004-5
• Table 4.53: Sanofi-Aventis anti-infectives R&D product pipeline, 2006
• Table 4.54: Merck' s anti-infectives product portfolio, 2004-5
• Table 4.55: Merck' s anti-infectives R&D product pipeline, 2006
• Table 4.56: Johnson & Johnson anti-infectives product portfolio, 2004-5
• Table 4.57: Johnson & Johnson' s anti-infectives R&D product pipeline, 2006
• Table 4.58: Roche' s anti-infectives product portfolio, 2004-5
• Table 4.59: Roche' s anti-infectives R&D product pipeline, 2006
• Table 4.60: Wyeth' s anti-infectives product portfolio, 2004-5
• Table 4.61: Wyeth' s anti-infectives R&D product pipeline, 2006
• Table 4.62: Abbott' s anti-infectives product portfolio, 2004-5
• Table 4.63: Abbott' s anti-infectives R&D product pipeline, 2006
• Table 4.64: Schering-Plough' s anti-infectives product portfolio, 2004-5
• Table 4.65: Schering-Plough' s anti-infectives R&D product pipeline, 2006